ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)- -FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 mil ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

Global Hereditary Angioedema Therapeutic Market is valued at approximately USD 4.42 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period ...

KalVista Pharmaceuticals, Inc. today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) ...

Quisitive Technology Solutions, Inc. ("Quisitive" or the "Company") is pleased to announce that two leading independent proxy advisory firms, including Institutional Shareholder Services Inc. ("ISS"), ...

DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...

The options have an exercise price of $7.90 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments ...

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D ...